GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ulisse Biomed SpA (MIL:UBM) » Definitions » Net Issuance of Debt

Ulisse Biomed SpA (MIL:UBM) Net Issuance of Debt : €-0.01 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ulisse Biomed SpA Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Ulisse Biomed SpA's net issuance of debt for the six months ended in Dec. 2024 was €0.05 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.01 Mil.

Ulisse Biomed SpA Net Issuance of Debt Historical Data

The historical data trend for Ulisse Biomed SpA's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ulisse Biomed SpA Net Issuance of Debt Chart

Ulisse Biomed SpA Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Issuance of Debt
Get a 7-Day Free Trial - - - - -0.01

Ulisse Biomed SpA Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - -0.06 0.05

Ulisse Biomed SpA Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ulisse Biomed SpA Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Ulisse Biomed SpA's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ulisse Biomed SpA Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ulisse Biomed SpA (MIL:UBM) » Definitions » Net Issuance of Debt
Comparable Companies
MIL:ARBS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270 SMMT RPRX XKRX:196170 OCSE:GMAB INSM BMRN HKSE:02269 SHSE:603392 INCY
Traded in Other Exchanges
N/A
Address
Area Science Park - SS14 km.163, 5, Basovizza, ITA, 34149
Website
https://www.ulissebiomed.com
Ulisse Biomed SpA is a healthcare biotech company. It is engaged in developing medical diagnostics, theranostics, and therapeutics solutions. The company has three technology platforms, namely, Sagitta for molecular diagnostics, NanoHybrid for theranostics and diagnostics, and Aptavir for therapeutics.

Ulisse Biomed SpA Headlines

No Headlines